These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11336575)

  • 21. Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).
    Graham GG; Graham RI; Day RO
    Curr Pharm Des; 2002; 8(12):1063-75. PubMed ID: 11945151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
    Everts B; Währborg P; Hedner T
    Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.
    Maddrey WC; Maurath CJ; Verburg KM; Geis GS
    Am J Ther; 2000 May; 7(3):153-8. PubMed ID: 11317164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
    Tindall E
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The coxibs, selective inhibitors of cyclooxygenase-2.
    FitzGerald GA; Patrono C
    N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
    [No Abstract]   [Full Text] [Related]  

  • 27. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclooxygenase-2 specificity and its clinical implications.
    Lefkowith JB
    Am J Med; 1999 May; 106(5B):43S-50S. PubMed ID: 10390127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COX-2 inhibition and colorectal cancer.
    Koehne CH; Dubois RN
    Semin Oncol; 2004 Apr; 31(2 Suppl 7):12-21. PubMed ID: 15252926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2-Selective NSAIDs: new and improved?
    Lichtenstein DR; Wolfe MM
    JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
    [No Abstract]   [Full Text] [Related]  

  • 33. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D; Nissen SE; Topol EJ
    JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS
    Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2 inhibitors in glioma therapy.
    Giglio P; Levin V
    Am J Ther; 2004; 11(2):141-3. PubMed ID: 14999366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
    South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
    N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.